This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Sharon Longhurst
Head of CMC at Immunicum


Sharon has 20 years’ experience of product and process development for biological products and ATMPs. Her experience encompasses 6 years in contract manufacture of gene therapy vectors for clinical studies, 6 years as a Quality Assessor at the MHRA, where she was a member of the GTWP and an active participate at the BWP, both working parties of the EMA at that time. A period of CMC/regulatory consulting at PAREXEL International followed before she moved back into industry; firstly in AKARI Therapeutics where she was responsible for all CMC related activities and CMC regulatory strategy for a recombinant protein, and for the past 2 years at IMMUNICUM AB as Head of CMC. Immunicum are developing a dendritic cell therapy for the treatment of solid tumours in combination with CPI/TKI, with an active process development program of work being performed in readiness for phase 3 clinical development and ultimately commercial supply.

Agenda Sessions

  • Allogeneic Immunotherapy for Renal Cell Cancer


Speakers at this event